🇺🇸 FDA

Company profile · Sponsor

Alnylam

Alnylam Netherlands B.V.

ALNY · NYSE pharma CAMBRIDGE, MA, EU
Pipeline
24
Drugs
8
Patents
8

Quick answer

Alnylam (ALNY) is a pharma company. headquartered in CAMBRIDGE, MA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 8 drugs, and 8 patents to this profile..

Company facts

Ticker ALNY
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, EU
SEC CIK 0001178670

Pipeline (24)

Search pipeline →

  1. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  2. 0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  3. ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy

    phase 3 small molecule active

    1 trial

  4. Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  5. Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.

    Alnylam

    Hereditary Transthyretin Amyloidosis

    phase 3 small molecule active

    1 trial

  6. Givosiran

    Alnylam

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

  7. Lumasiran

    Alnylam

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  8. Lumasiran

    Alnylam

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  9. Nucresiran

    Alnylam

    Transthyretin Amyloidosis With Cardiomyopathy

    phase 3 small molecule active

    1 trial

  10. Nucresiran

    Alnylam

    Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

    phase 3 small molecule active

    1 trial

  11. Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v

    Alnylam

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  12. Patisiran

    Alnylam

    Amyloidosis

    phase 3 small molecule completed

    1 trial

  13. Patisiran

    Alnylam

    Amyloidosis, Familial

    phase 3 small molecule completed

    1 trial

  14. Patisiran

    Alnylam

    Amyloidosis, Hereditary

    phase 3 small molecule completed

    1 trial

  15. Placebo

    Alnylam

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  16. Placebo

    Alnylam

    Primary Hyperoxaluria Type 1 (PH1)

    phase 3 small molecule completed

    1 trial

  17. Placebo for Nucresiran, ALN-TTRSC04

    Alnylam

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  18. Revusiran (ALN-TTRSC)

    Alnylam

    Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    phase 3 small molecule completed

    1 trial

  19. Vutrisiran

    Alnylam

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule active

    2 trials

  20. Zilebesiran

    Alnylam

    High Risk Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  21. patisiran (ALN-TTR02)

    Alnylam

    TTR-mediated Amyloidosis

    phase 3 small molecule completed

    1 trial

  22. ALN-2232

    Alnylam

    Obesity

    phase 2 small molecule active

    1 trial

  23. ALN-4324

    Alnylam

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  24. ALN-4324

    Alnylam

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

Drugs (8)

Search drugs →

  1. givosiran

    GIVLAARI

    A16AX16

  2. givosiran sodium

    GIVLAARI

    SUBCUTANEOUS approved

  3. lumasiran

    OXLUMO

    A16AX18

  4. lumasiran sodium

    OXLUMO

    SUBCUTANEOUS approved

  5. patisiran

    ONPATTRO

    N07

  6. patisiran sodium

    ONPATTRO

    INTRAVENOUS approved

  7. vutrisiran

    AMVUTTRA

    N07XX18

  8. vutrisiran sodium

    AMVUTTRA

    SUBCUTANEOUS approved

Patents (8)

Search patents →

  1. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12397013

    Extrahepatic delivery

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12385044

    Modified double-stranded RNA agents

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12385043

    Modified double-stranded RNA agents

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12378553

    Modified double-stranded RNA agents

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12364762

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12350338

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Alnylam?

Alnylam (ALNY) is a pharma company. headquartered in CAMBRIDGE, MA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 8 drugs, and 8 patents to this profile..

What pipeline programs does Alnylam sponsor?

We track 24 ClinicalTrials.gov-linked programs for Alnylam, including 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Alnylam company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.